Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
1 2 3 4 5 … 49 Next »

Tremfya vs Stelara Italian study

Threaded Mode
Tremfya vs Stelara Italian study
Fred Online
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 57,003
Threads: 3,553
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 1
Psoriatic Arthritis Score: 1
PQOLS: 2
Treatment: Bimzelx / Coconut Oil
#1
News  Thu-26-01-2023, 22:32 PM
Comparing Tremfya to Stelara 104-week multicentre retrospective study in Italy.

Quote:
Background:
Guselkumab is a humanized monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial.

Objectives:
We conducted a 104-week multicenter retrospective study to assess the effectiveness and safety of guselkumab in patients affected by plaque psoriasis with an inadequate response to ustekinumab in a real-life setting.

Methods:
Our retrospective study included 233 adults affected by moderate-to-severe plaque psoriasis, enrolled in 14 different Italian centers, and treated with guselkumab after failing therapy with ustekinumab. Patient characteristics and PASI (Psoriasis Area and Severity Index) score at each visit (baseline, weeks 16, 52 and 104) were recorded. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI, compared with baseline, were registered.

Results:
At week 52, PASI 75 was reached by 89.88% of patients, PASI 90 by 71.43%, PASI 100 by 58.83% and absolute PASI ≤ 2 by 90.48%. At week 104, similar effectiveness results were observed. Compared to the NAVIGATE trial, we observed higher rates of PASI 75/90/100. Patients with the involvement of difficult-to-treat areas were significantly less likely to achieve PASI90 and PASI100 at week 16. Obese patients had significantly lower rates of PASI75 and PASI≤2 at week 52. At week 104, comparable responses were observed among all patients’ subgroups, regardless of BMI status, involvement of difficult-to-treat areas, presence of cardiometabolic comorbidities and concomitant psoriatic arthritis. No significant safety findings were reported throughout the study.

Conclusion:
Our data suggest that the efficacy of guselkumab in patients with inadequate response to ustekinumab for plaque psoriasis in “real-life” clinical practice is comparable with NAVIGATE study with higher percentages of patients achieving PASI90 and PASI100 at weeks 16, 52 and 104.

Source: onlinelibrary.wiley.com

*Early view funding unknown. 

Tremfya (guselkumab)

Stelara (ustekinumab)
Quote
Caroline Online
You must hurry if you ever want to catch a chicken...
*
Forum Helper
Posts: 21,930
Threads: 105
Joined: Nov 2011
Gender: Female
Location: In between the tulips
Psoriasis Score: 3
Psoriatic Arthritis Score: 3
PQOLS: 4
Treatment: Got back to DMF slow release
#2
Fri-27-01-2023, 08:15 AM
It’s great that PASI’s of 90 and 100 are being reached. So much relief for the patients.
Quote
Fred Online Author
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 57,003
Threads: 3,553
Joined: Aug 2011
Gender: Male
Location: France
Psoriasis Score: 1
Psoriatic Arthritis Score: 1
PQOLS: 2
Treatment: Bimzelx / Coconut Oil
#3
Fri-27-01-2023, 12:39 PM
(Fri-27-01-2023, 08:15 AM)Caroline Wrote: It’s great that PASI’s of 90 and 100 are being reached. So much relief for the patients.

Yep
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Psoriasis and cardiovascular study Fred 2 464 Fri-24-03-2023, 21:41 PM
Last Post: Kat
News Delphi study into generalized pustular psoriasis Fred 0 416 Sat-07-01-2023, 14:17 PM
Last Post: Fred
News Otezla (apremilast) quality of life, efficacy, and safety study Fred 1 764 Tue-01-11-2022, 03:14 AM
Last Post: mataribot
News Ilumetri / Ilumya 52 week Italian study Fred 2 671 Wed-28-09-2022, 03:09 AM
Last Post: mataribot
News Tremfya going after psoriatic arthritis Fred 12 5,920 Sun-14-08-2022, 19:08 PM
Last Post: Caroline



Users browsing this thread: 1 Guest(s)
    Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2023 Psoriasis Club All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode